Switzerland's 2025 healthcare law outlines a complex regulatory framework for medical devices, pharmaceuticals, cosmetics, biocides, and emerging technologies like AI and mHealth.

Wang, Markus / Schweikard, Christine, Medizinprodukte – Marktzugang und Vergütung in der obligatorischen Krankenpflegeversicherung...

Designed specifically for in-house counsel in the life sciences industry, the event focused on the complexities and challenges faced in managing Supply Chain Disputes, covering litigation strategies, termination risks...

At the beginning of September 2025, the Swiss Federal Council published the dispatch for the partial revision of the Therapeutic Products Act (TPA).

Swiss Life erwirbt sämtliche Aktien der GHZ Gewerbe- und Handelszentrum Schlieren AG (GHZ) und stärkt damit ihren Immobilienbereich im Life-Science-Sektor.

MoonLake Immunotherapeutics (MoonLake; Nasdaq: MLTX), a Swiss clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases...

This case concerns infringement by Glenmark on Novartis' SPC 300451 for eltrombopag (marketed as Revolade®). Novartis sought urgent relief after Glenmark included its generic "Eltrombopag Glenmark"...

Narcosis, whippped cream, engine tuning or party drug: laughing gas has many uses in Switzerland. But what is the legal classification of laughing gas...

Bär & Karrer, a Swiss law firm, provides comprehensive legal and business solutions. Contact their Zurich office for expert assistance with legal advice, business inquiries, and professional services tailored to your needs.

On March 21, 2025, the Swiss parliament has adopted a new Cost Containment Package ("CCP2") in response to the continuing rise of healthcare costs...

Bär & Karrer stands at the forefront of life sciences and healthcare law, offering one of the most comprehensive practices in Switzerland. With a team of 15 partners and 12 associates, the firm advises a diverse...

Consultations on the revision of the Swiss Therapeutic Products Act and the Epidemics Act are ongoing until 22 March 2024. What can Swiss healthcare stakeholders...

Last month, Germany introduced the Digital Health Service Act, which grants German patients access to reimbursable digital health applications.

After some delays, the implementation of swissdamed – the Swiss Database on Medical Devices – is now picking up speed. Below you can find out what the current timetable...

First set of measures was adopted by the federal parliament in June 2021.

The most recent measures implemented for the pharmaceutical sector by the Swiss Federal Council and the Federal Department of Home Affairs effective from 1 May 2012 mean further losses for the pharmaceutical companies in Switzerland.

The Swiss government wants to encourage the use of biosimilars and generics with the aim of decreasing the costs of healthcare.

Kaum ein Bereich ist in jüngster Zeit so stark unter Druck geraten wie die Gesundheitsgesetzgebung – von der Bewältigung der COVID-19-Pandemie bis hin zu datenschutzrechtlichen Herausforderungen hinsichtlich Digitalisierung.

Vicky Walker, an experienced French surgeon, came up with an innovative idea about a hip joint that can be worn externally, without requiring surgery.

What are important changes in regulation and what is to be expected from the markets in 2024? The co-heads of Kellerhals Carrard's Life Sciences Practice Group share their perspective on key developments.